EMA
approval
· 2026-08-27
EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o
Summary
Authorised new medicine Bilprevda (denosumab) by Sciencepharma Sp. z o.o. for Giant Cell Tumor of Bone and bone neoplasms.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Sciencepharma Sp. z o.o. Decision date: 13/07/2026